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Abstract: Antibody-drug conjugates (ADCs) are promising state-of-the-art biopharmaceutical drugs
for selective drug-delivery applications and the treatment of diseases such as cancer. The idea behind
the ADC technology is remarkable as it combines the highly selective targeting capacity of monoclonal
antibodies with the cancer-killing ability of potent cytotoxic agents. The continuous development
of improved ADCs requires systematic studies on the nature and effects of warhead modification.
Recently, we focused on the hydrophilic modification of monomethyl auristatin E (MMAE), the most
widely used cytotoxic agent in current clinical trial ADCs. Herein, we report on the use of micellar
electrokinetic chromatography (MEKC) for studying the hydrophobic character of modified MMAE
derivatives. Our data reveal a connection between the hydrophobicity of the modified warheads as
free molecules and their cytotoxic activity. In addition, MMAE-trastuzumab ADCs were constructed
and evaluated in preliminary cytotoxic assays.
Keywords: antibody-drug conjugate; biopharmaceutical; cytotoxicity; hydrophobicity; micellar
electrokinetic chromatography
1. Introduction
Natural science has witnessed many breakthroughs during the past decades. The new biological
insights gained, the improved biochemical protocols and analytical tools developed, and the constant
advances in chemical reaction technologies have paved the way for exciting and multidisciplinary
research fields such as the field of antibody-drug conjugates (ADCs). ADCs are modern drug-delivery
molecules that combine the selective targeting capabilities of monoclonal antibodies (mab) with the
potent cytotoxicity displayed by toxic organic compounds [1,2]. The interest toward ADCs and
the investments in ADC research have increased exponentially in recent years as a result of the
U.S. Food and Drug Administration (FDA) approval of brentuximab vedotin (Adcetris®) in 2011
(for relapsed cases of Hodgkin’s lymphoma and anaplastic large cell lymphoma) [3], trastuzumab
emtansine (Kadcyla®) in 2013 (for human epidermal growth factor receptor 2 -positive metastatic
breast cancer) [4], gemtuzumab ozogamicin (Mylotarg®) in 2017 (for acute myeloid leukemia) [5], and
inotuzumab ozogamicin (Besponsa®) in 2017 (for acute lymphoblastic leukemia) [6].
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The development of modern ADCs requires systematic research on antibodies, bioconjugation
technologies, as well as information on the properties of the payload molecules and the characteristics
of the end products. Recently, hydrophilic derivatization of payload molecules was reported to have
beneficial effects on the overall properties of the ADCs, for example, on the therapeutic index and the
pharmacokinetics [7,8]. In line with the current research trends, we developed an alternative strategy
for increasing the hydrophilicity of the cytotoxic agents based on the incorporation of carbohydrates
and we constructed a limited set of monomethyl auristatin E (MMAE)-carbohydrate hybrids [9].
MMAE (see the structure displayed in Figure 1) is an antineoplastic and antimitotic drug that
appears as the cytotoxic agent in at least sixteen ADCs which have progressed to clinical trials [10,11].
Among these is the ADC brentuximab vedotin, which is used in the treatment of relapsed cases of
Hodgkin’s lymphoma and anaplastic large cell lymphoma [3]. On a more general level, MMAE and
other auristatins have become important cytotoxic agents for ADC development since they tolerate
covalent structural modifications without substantial loss of cytotoxic activity. While this is beneficial,
the hydrophobic nature of MMAE and especially current MMAE-linker conjugates is sub-optimal
for the development of ADCs with high drug-to-antibody ratios. This is because the attachment of
multiple drug-linker moieties of this kind may lead to devastating effects on the biocompatibility
and pharmaceutical efficacy of the end products. These problems are reflected in the design of
current ADCs where focus is placed on low drug-to-antibody ratios, typically in the range of 2–4.
In addition, multi-drug resistant cancer cells tend to overexpress efflux pump proteins capable of
removing hydrophobic cytotoxic agents from the intracellular environment, thus further diminishing
their potential [12]. The incorporation of hydrophilic moieties in the cytotoxic agents or the payload
molecules has been identified as a valid strategy for overcoming these challenges and circumventing
issues related to unwanted aggregation and clearance of ADCs [13]. To date, hydrophilic linkers based
on polyethylene glycol (PEG) [7], the sulfonate group [8], and carbohydrates [9] have been reported.
We have previously focused on the inclusion of hydrophilic carbohydrates in the linker species and the
cytotoxic agent due to their biocompatibility, pre-existing degradation routes, further derivatization
possibilities, and, just as important, low cost.
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the relative hydrophobicities of MMAE and representatives of our own modified auristatins, namely, 
β-d-glucuronyl-monomethylauristatin E (MMAU, compound 1 in Figure 1) and an MMAE-
glycolinker-substrate (compound 2 in Figure 1), by micellar electrokinetic chromatography (MEKC) 
using sodium dodecyl sulfate and sodium cholate as surfactants. Furthermore, cytotoxic assays 
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A thorough investigation of the change in the hydrophobic character was not included in
the previous studies, even though it is important in understanding the nature of the modified
molecules and the effects of the chosen strategy. Therefore, we continue our studies in this work
by determining the relative hydrophobicities of MMAE and representatives of our own modified
auristatins, namely, β-d-glucuronyl-monomethylauristatin E (MMAU, compound 1 in Figure 1) and
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an MMAE-glycolinker-substrate (compound 2 in Figure 1), by micellar electrokinetic chromatography
(MEKC) using sodium dodecyl sulfate and sodium cholate as surfactants. Furthermore, cytotoxic
assays reveal an obvious connection between the hydrophobic properties of the warhead molecules
and their corresponding cytotoxicity. Due to the mechanism by which ADCs function (internalization
followed by the release of the cytotoxic agent), it was important to analyze the cytotoxic profiles
of eventual end products in addition to those of the free warhead molecules. As a result,
trastuzumab-auristatin derivatives, which can be used to treat HER2-positive breast cancer patients,
were constructed and their cytotoxicities were screened.
2. Materials and Methods
2.1. Chemicals
Reagents and solvents were purchased from commercial sources. Reactions solvents were dried
and distilled prior to use when necessary. All reactions containing moisture- and/or air-sensitive
reagents were carried out under argon atmosphere.
2.2. Capillary Electrophoresis
A Hewlett Packard 3DCE (Agilent, Waldbronn, Germany) instrument was used for all capillary
electrophoresis (CE) runs. Uncoated fused silica capillary (length 30/38.5 cm) was obtained from
Polymicro Technologies (Phoenix, AZ, USA) and the inner and outer diameters of the capillary
were 50 µm and 375 µm, respectively. The separation voltage was 25 kV and the capillary cassette
temperature was kept constant at 25 ◦C. Samples were injected at 10 mbar for 10 s. Thiourea (0.5
or 0.2 mM) was used as an electroosmotic flow (EOF) marker and 10 mM (ionic strength) sodium
phosphate buffer at pH 7.4 was used as the background electrolyte (BGE) solution for CE runs. In
MEKC studies, the surfactants were dispersed in the same BGE solution. New capillaries were
preconditioned by rinsing for 15 min with 0.1 M sodium hydroxide, 15 min with water, and for 2–5 min
with the CE or MEKC BGE solution. All runs were repeated at least five times.
2.3. Calculations of Retention Factors and Distribution Constants
The retention factor (k) in chromatography is a description of the time the sample component
resides in the stationary phase (or pseudostationary phase, PSP) relative to the time it resides in
the mobile phase. The expression states how much longer a sample component is retarded by the
stationary phase than it would take to travel through the column or capillary with the velocity of the
mobile phase. In the case of CE techniques, the stationary phase is either stationary as in capillary
electrochromatography or pseudostationary as in electrokinetic capillary chromatography. The velocity
of the mobile phase is based on the velocity of the EOF; however, external pressure assistance is also
possible. In this work we used the EKC mode and here the retention factor describes the molar ratio of
an analyte in a PSP and in an aqueous mobile phase, that is, ( nPSPnaq ). From this expression it is obvious
that the retention factor in EKC is dependent on the PSP concentration. In MEKC the retention factor
can be calculated using Equation 1, when the effective electrophoretic mobility of the analyte under
MEKC (µMEKC) and CE conditions (µ0) is known, as well as the effective electrophoretic mobility of
the micelles (µPSP):
k =
uMEKC − u0
uPSP − uMEKC . (1)
An iteration procedure employing a homologous series of alkylbenzoates was used for estimating
the µPSP, as previously reported [14,15]. The resulting values for 20 mM sodium dodecylsulfate (SDS)
and for 20 mM SDS mixed with 40 mM sodium cholate (SC) (hereafter called 20/40 mM SDS/SC) were
−4.32E-08 and −4.06E-08 m2·V−1s−1, respectively.
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The distribution constant (KD) is the molar concentration ratio of an analyte between a
pseudostationary phase and an aqueous phase and it can be calculated for systems with known
phase ratios (φ) using Equation (2):
KD =
k
φ
(2)
The phase ratio is the volume ratio of the pseudostationary phase and the aqueous phase in the
fused silica capillary and it can be calculated from Equation (3):
φ =
VPSP
Vaq
=
νspec, vol ·M·(cPSP − CMC)
1−
(
νspec, vol ·M·(cPSP − CMC)
) , (3)
where VPSP and Vaq are the volumes of the pseudostationary phase and the aqueous phase in the
capillary, respectively, νspec,vol is the partial specific volume, M is the molar mass, CPSP is the total
concentration of the surfactants, and CMC is the critical micelle concentration of the surfactants. The
partial specific volumes of SDS and SC in phosphate buffer at pH 7.4 (I = 10 mM) were approximated
to be close to the value in water at 25 ◦C and therefore values of 0.853 mL·g−1 and 0.749 mL·g−1,
respectively, were used [16,17]. The partial specific volumes of the SDS/SC mixed micelles were
estimated based on the used surfactant concentration ratios.
2.4. Determination of the Critical Micelle Concentration
For the phase ratio calculation, the surfactant CMCs in sodium phosphate buffer
(pH 7.4, I = 10 mM) were determined with an optical contact angle meter using the pendant drop
method (CAM 200 Optical Contact Angle Meter, Biolin Scientific, Espoo, Finland). Surface tensions of
the surfactant solutions at different concentrations were determined by taking images of the pendant
drops (4 drops/concentration, 20 frames/drop) with a CCD Video camera module and fitting a
Young–Laplace equation to the frames using an Attension Theta Software (ver. 4.1.0. Biolin Scientific,
Espoo, Finland). All measurements were repeated three times. The resulting CMCs for SDS and for
the 20/40 SDS/SC mixture were 5.08 ± 0.24 and 6.00 ± 0.38 mM, respectively.
2.5. Preparation of Drug-Linker Compounds and Antibody-Drug Conjugates
MMAU and ε-maleimidocaproyl-L-valine-L-citrulline-paraaminobenzyloxycarbonyl-paranitrophenyl
(MC-Val-Cit-PABC-pNP) were prepared as described previously [18]. Interchain disulphide bridges of
trastuzumab (Herceptin®, Roche, Espoo, Finland) were reduced with tris(2-carboxyethyl)phosphine (TCEP)
and antibody drug-conjugates (ADCs) were synthesized by incubating 0.1 mM TCEP-reduced antibody
with 50× molar excess of either MC-Val-Cit-PABC-MMAU or MC-Val-Cit-PABC-MMAE drug-linker
compound as described by Satomaa et al. [18]. Non-conjugated drug-linkers were removed by repeated
additions of formulation buffer (i.e., 5% mannitol-0.1% Tween-PBS) and centrifugation through Amicon
Ultracel 30 K centrifugal filter (Merck KGaA, Darmstadt, Germany). In order to characterize the compounds,
30 µg of each ADC was digested with FabRICATOR enzyme (Genovis, Lund, Sweden) and analyzed with
MALDI-TOF mass spectrometry using sinapinic acid matrix. After this, the drug-to-antibody ratios were
calculated based on the observed relative intensities of the light chain fragments (LC) at m/z 24926 (LC +
MMAU), Fab heavy chain fragments (Fab-HC) at m/z 29854 (Fab-HC + 3 MMAU), and Fc heavy chain
fragments (Fc) at m/z 25227, 25389, and 25551 for differentially galactosylated fragments G0F-Fc, G1F-Fc,
and G2F-Fc, respectively [18]. Both ADCs were similarly analyzed and found to have a drug-to-antibody
ratio of 8.
2.6. Cytotoxicity Assay
In vitro cytotoxicity of the free payloads and ADCs was assayed similarly as described before [9].
Briefly, a human ovarian cancer cell line SKOV-3 (ATCC, Manassas, VA, USA) was seeded in cell
culture medium onto 96-well plates and incubated overnight in a cell incubator. Dilution series of
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free payloads and antibody-drug conjugates were applied to the cells in three parallel wells and the
incubation was continued for 72 h. The viability of the cells was determined with PrestoBlue cell
viability reagent (Life Technologies, Carlsbad, CA, USA) according to the manufacturer’s instructions.
The reagent was incubated with cells for 2–2.5 h and the absorbance was measured at 570 nm and
600 nm. IC50 values were determined using curve fitting by nonlinear regression as the concentration
of the drug that causes 50% inhibition of cell viability compared to maximum inhibition.
3. Results and Discussion
3.1. Micellar Electrokinetic Chromatography
The hydrophobic character of the cytotoxic agents displayed in Figure 1 was assessed using MEKC.
The technique is excellent for the separation of charged and neutral compounds, and particularly
for assessing the hydrophobicity of analytes. In MEKC the fused silica separation capillary is filled
with amphiphilic surfactants, which are able to coalesce to form micelles at concentrations exceeding
the critical micelle concentration [19–22]. Generally, liposomes and micelles are accepted models
for interpreting the interactions between molecules and lipid bilayers, and therefore studying the
interaction of the payload molecules in this system creates a simplified model for studying the
interactions of the liberated drugs with cellular membranes. This is undoubtedly an important factor
for antibody-drug conjugates as a whole. Therefore, the results of the MEKC studies generate more
information than theoretically calculated partitioning coefficients or distribution constants (i.e., logP or
logD values), especially from a biological perspective.
To evaluate the hydrophobicity of the cytotoxic agents MMAE, 1, and 2 (see Figure 1), the retention
factors (k) and, moreover, the distribution constants (KD) of the compounds were determined using
negatively charged, highly hydrophobic SDS micelles, and a mixture of SDS and less hydrophobic
SC micelles as pseudostationary phase in MEKC. Since the distribution constant of a compound
in electrokinetic chromatography illustrates the strength of interaction between the compound and
the pseudostationary phase, the value directly reflects the hydrophobicity of the compound; the
higher the interaction, the higher is the distribution constant, and consequently, the higher is the
hydrophobicity of the compound. The distribution constants, and the logarithm of the distribution
constants, of the compounds using 20 mM SDS and 20/40 mM SDS/SC dispersions were calculated
using Equations (1)–(3) (in the experimental section) and the values are shown in Figure 2. The
corresponding electropherograms are shown in Figure 3.
SDS is the most frequently used surfactant in MEKC, and therefore the hydrophobicity of the
auristatins was initially assessed using solely SDS micelles. From the experimental data it was obvious
that the attachment of carbohydrates containing hydrophilic functional groups to MMAE decreased
the hydrophobicity of the parent molecule in the order of MMAE > 2 > 1. In more detail, the KD
value decreased by 13% when the N-terminal of MMAE was modified by reductive amination with
6-deoxy-6-azido-D-galactose to give compound 2, whereas the decrease was 36% when the benzylic
hydroxyl group in the norephedrine residue was modified by glycosylation with glucuronic acid to
give compound 1. The distribution constants, that is, the relative hydrophobicity of the cytotoxic
agents, are logical. The modification of the N-terminal of MMAE, which gives rise to 2, adds a
hydrophilic tail to the molecule containing four hydroxyl groups. Surprisingly, this modification
does not significantly alter the hydrophobic character of MMAE. The attachment of a glucuronic
acid to the benzylic hydroxyl group of MMAE resulting in 1 is associated with a greater increase
in hydrophilic character, especially compared to 1. This is logical since glucuronic acid contains a
carboxylic acid functionality in addition to the hydroxyl groups. A 36% decrease in the distribution
constant is considerable, especially since the structural variations between 1 and 2 are relatively small.
Separations 2019, 6, 1 6 of 12
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The obtained results are consistent with theoretical octanol-water coefficients (logD) calculated
by the ChemAxon software. The software estimates the logD values based on the structures of
the compound as a function of pH, and the resulting logD values at pH 7.4 were 2.0, 1.1, and
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−0.43 for MMAE, 2, and 1, respectively (shown as red lines in Figure 2). The logD values of the
compounds follow the same order as the experimental logKD values; however, the logD values were
two to eight times lower and the differences between the logD values of the compounds were larger.
The high experimentally determined logKD values can be explained by the selection of SDS as the
pseudostationary phase. SDS is a well-established anionic surfactant forming spherical micelles with
a hydrophobic interior and a negatively charged hydrophilic exterior. These micelles are highly
hydrophobic and, thus, the selectivity for neutral, highly hydrophobic, and fairly large compounds
can be poor due to their nearly complete solubilization into the SDS micelles, resulting in co-migration
of compounds [20,23–25]. In addition, SDS micelles are stronger hydrogen bond donors than 1-octanol
and therefore they are expected to have strong interactions with hydrogen bond acceptor solutes like
MMAE and its derivatives. Due to the poor selectivity of SDS micelles toward the used analytes,
sodium cholate (SC), a biologically relevant anionic surfactant, was tested. SC is a common bile salt
having a steroidal structure and it has been shown to be advantageous for separating hydrophobic
compounds that cannot be separated by SDS [25–27].
Surprisingly, pure 40 mM SC micelles did not have any interaction with the cytotoxic agents
(data not shown) and therefore different mixed micellar systems of SDS and SC were tested (20/10,
20/20, and 20/40 mM of SDS/SC). The addition of 10, 20, or 40 mM SC to the SDS solutions
lowered the hydrophobicity of the SDS micelles in all cases, as witnessed by improved separations
of the compounds with the optimal separation achieved by mixing 20 mM SDS with 40 mM SC.
The compounds followed the same migration order as with pure SDS micelles (1 > 2 > MMAE),
but the separation selectivity was much enhanced using a mixed SC and SDS system. With this
pseudostationary phase, the hydrophobicity (KD) decreased by 66% for compound 2 and by 84%
for compound 1 (Figure 2B). Moreover, the logKD values, obtained using the 20/40 mM SDS/SC
mixture, were in a better correlation with the theoretical logD values than the values obtained using
solely SDS as a pseudostationary phase (Figure 2B). One plausible explanation is that polar SC has a
weaker solubilization power than SDS, and thus the SC/SDS mixture is a better model for biological
systems [20].
3.2. Trastuzumab Conjugates and Cytotoxicity Assays
In our previous study, the cytotoxicities of MMAE (IC50 = 4 nM), 2 (IC50 = 12 nM), and
an MMAE-glycolinker-cetuximab ADC (IC50 = 9 nm) were reported using HSC-2 head-and-neck
squamous cell carcinoma cells [9]. It was rather surprising that the cytotoxicity displayed by MMAE
was only marginally reduced when the N-terminal was modified with a glycolinker, since previous
studies have established that an amide bond at the same site leads to the loss of cytotoxic activity [28].
While stable linkers have been found to improve the tolerability and antitumor activity in other
state-of-the art ADCs (e.g., the anti-HER2 ADC trastuzumab emtansine) [29], the glycolinker strategy
failed to yield a superior ADC and the approach was not considered competitive enough.
Therefore, we decided to use a cleavable linker in this study. While a number of cleavable
linkers exist (e.g., pH-sensitive linkers, enzyme targeting linkers) [25,26], we opted to use the
cathepsin B cleavable linker valine-citrulline-p-aminocarbamate (Val-Cit-PABC) which is currently
used in brentuximab vedotin [30]. Furthermore, we decided to evaluate the effects of the
hydrophilic glucuronic acid residue at the hydroxyl group in the norephedrine residue of MMAE
(the MMAE-glycolinker-substrate was thus not re-evaluated). In addition, it should be noted that the
proteolysis of the Val-Cit-PABC-linker releases the warhead molecule as such instead of a conjugate
thereof [31]. Therefore, it was important to start by evaluating the cytotoxicity of MMAE and MMAU
(see Figure 1).
SKOV-3 ovarian carcinoma cells expressing the HER2 receptor protein were used, and the results
are summarized in Figure 4. When evaluating the cytotoxicity using this cell line, MMAU was over
three orders of magnitude less cytotoxic than MMAE when applied to the cell culture medium. It is
therefore clear that an increase in the hydrophilic character of the MMAE derivatives is accompanied by
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a decrease in the cytotoxic activity displayed. Based on these results alone, increasing the hydrophilicity
and a steric bulk of the norephedrine-residue leads to a substantial decrease in the cytotoxicity of the
parent molecule in contrast to the previous hydrophilic modification of the N-terminal. This may be
related to the cellular uptake mechanism, which favors hydrophobic molecules, or to the binding mode
by which the auristatins act at the tubulin receptor [32,33]. The first mechanism seems more plausible
since we have established that MMAU displays an effective bystander effect when conjugated to an
internalizing antibody such as an ADC [18]. This further indicates that the glucuronide is hydrolyzed
in the intracellular milieu thus liberating the actual drug, namely, MMAE.Separations 2018, 5, x FOR PEER REVIEW  8 of 12 
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These results prove that the construction of competitive ADCs can be achieved by the use of
cytotoxic warheads that would normally be disregarded based on cytotoxicity assays alone. On a
more fundamental level, the question that arises is why ADCs are not regularly screened for the
delivery of hydrophilic agents across the cellular membrane, that is, molecules that would normally
not pass the membrane. This is an area which requires further research and as our preliminary study
on the cytotoxicity of the trastuzumab-auristatin ADCs shows, there is a significant potential for the
development of novel ADCs with hydrophilic payload molecules. While we have focused on the use
of carbohydrates as a means of increasing the hydrophilicity, other strategies have also been reported
(e.g., the use of charged phosphate groups) [35]. It is clear that there is a need for more systematic
studies with larger molecule libraries featuring hydrophilic and hydrophobic warhead molecules
in order to provide detailed insights on the subject. Nonetheless, the benefits of carbohydrates are
related to their specific lysosomal cleavage pathways in human cells, which provide an elegant way of
adding hydrophilicity to the ADCs during the systemic distribution and localization in target tissues.
Simultaneously, and using this pro-drug strategy, the fully active hydrophobic cytotoxic agent is
generated after ADC internalization in target cells. In a recent follow-up study, we have shown that
this concept is viable, since MMAU-ADCs show excellent cytotoxic activity against cancer cells both
in vitro and in vivo, where complete eradication of tumors in xenografted mice was achieved [18].
4. Conclusions
MEKC was used for determining the relative hydrophobicities of modified auristatins. Optimal
separation was achieved using a mixed micellar system of 20 mM SDS and 40 mM SC as the
pseudostationary phase. The hydrophobicity of the auristatins decreased in the order of MMAE
> compound 2 > compound 1, and the same pattern was identified in the cytotoxic assays where the
cytotoxicity decreased in the same order.
Hydrophilic modification (attachment of a glucuronic acid residue) at the norephedrine residue
of MMAE (compound 1; MMAU) was accompanied by a significant decrease in the cytotoxicity. The
addition of a hydrophilic glycolinker at the N-terminal, on the other hand, had only a slight effect on
the cytotoxicity (compound 2), which is an interesting observation since an amide bond at this position
is known to render the auristatins close to non-toxic.
The preliminary cytotoxic evaluation of the trastuzumab-MC-Val-Cit-PABC-auristatin conjugates
3 and 4 revealed IC50-values in the pM range. These values are comparable to other leading
state-of-the-art ADCs. Furthermore, the MMAU-ADCs have certain advantages over the MMAE-ADCs,
for example, prematurely cleaved linkers will be accompanied by less off-site harmful side effects due
to the lower cytotoxicity of MMAU when compared to MMAE. Altogether, our results on the use of
hydrophilic payload conjugates prove that novel opportunities exist for the future design of ADCs
with previously neglected hydrophilic molecules.
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